Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03874117 · ClinicalTrials.gov registry record · NA

Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function

A NA study of Kidney Failure, Chronic and Hemodialysis, sponsored by Palo Alto Veterans Institute for Research.

Completed
Registry status
NA
Development phase
58
Enrollment target
3
Study locations

NCT03874117 is a NA study of Kidney Failure, Chronic and Hemodialysis that has completed, run by Palo Alto Veterans Institute for Research. The registered enrollment target is 58 participants, below the 330-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03874117, a NA study of Kidney Failure, Chronic and Hemodialysis, has completed, sponsored by Palo Alto Veterans Institute for Research.

COMPLETED
Registry status
NA
Development phase
58 participants
Enrollment target
3
Study locations

Study Summary

The study will determine the efficacy of twice weekly hemodialysis in patients with residual kidney function.

Interventions

  • OTHER Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis
  • OTHER Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis

Study Locations (3)

California

  • VA Palo Alto Health Care System - Palo Alto
  • Santa Clara Valley Medical Center - San Jose
  • Satellite HealthCare - San Jose

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2018-07-01
Est. Completion 2025-05-31
Phase NA

What the Registry Record Tells You About NCT03874117

The ClinicalTrials.gov registry entry for NCT03874117 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 330-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (82% lower). The listed sponsor is Palo Alto Veterans Institute for Research, which has 35 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Kidney Failure, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis is the first listed.

NCT03874117 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03874117 about?

NCT03874117 is a clinical study titled "Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function". The study will determine the efficacy of twice weekly hemodialysis in patients with residual kidney function.

What is the current status of trial NCT03874117?

This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2018-07-01. Estimated completion is 2025-05-31.

What conditions does trial NCT03874117 study?

This clinical trial studies the following conditions: Kidney Failure, Chronic, Hemodialysis.

What interventions are being tested in trial NCT03874117?

The interventions under investigation include: Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis (OTHER), Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis (OTHER).

Who is sponsoring clinical trial NCT03874117?

This trial is sponsored by Palo Alto Veterans Institute for Research, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03874117 being conducted?

This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Kidney Failure, Chronic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.